AARA Research Center

Dallas, Texas 75231

0 studies enrolling now · 55 studies all time

What they study most

Agammaglobulinemia, Allergic Rhinitis, Angioedema, Antibody Deficiency, Asthma, Bilateral Nasal Polyposis, Chronic Cough, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Common Variable Immunodeficiency, HAE, Hereditary Angioedema

Studies at this site

• HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) — Running, not enrolling
• A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) — Running, not enrolling
• Study of PlasmaCap IG in Adults and Children With PIDD — Completed
• CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema — Completed
• Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks — Completed
• A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema — Completed
• Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients — Completed
• A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) — Completed
• A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema — Running, not enrolling
• A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema — Running, not enrolling
• A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency — Completed
• Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults — NO_LONGER_AVAILABLE
• CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks — Completed
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency — Completed
• A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema — Completed
• A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America — Completed
• A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) — Completed
• Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients — Completed
• A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children — Completed
• Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis — Completed
• GB001 in Adult Participants With Chronic Rhinosinusitis — Completed
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration — Completed
• A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE — Completed
• C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks — Completed
• A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) — Completed
• C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks — Completed
• Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks — Completed
• Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema — Completed
• Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE — Completed
• A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema — Completed
• Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks — Completed
• Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) — Completed
• Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema — Completed
• Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) — Completed
• Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects — Completed
• CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 — Completed
• Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE — Completed
• A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants — Completed
• Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) — Completed
• Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency — Completed
• A Dose Escalation Study of Bradanicline in Refractory Chronic Cough — Completed
• Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults — Stopped early
• Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety — Completed
• Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases — Completed
• Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE — Completed
• Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD) — Completed
• Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks — Completed
• A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis — Completed
• 3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis — Completed
• Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency — Completed